Search

Your search keyword '"Ducreux M"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Ducreux M" Remove constraint Author: "Ducreux M" Database OpenAIRE Remove constraint Database: OpenAIRE
47 results on '"Ducreux M"'

Search Results

1. Valorization of unsaturated dicarboxylic acids obtained from bio-fermentation of organic municipal wastes

3. Gender medicine and oncology: Report and consensus of an ESMO workshop

4. FFCD Prodige 31 Reminnet: a european, multicentre, phase II/III randomized double-blind, placebo-controlled study evaluating

5. REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

6. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona

8. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

9. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

12. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

13. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

14. Caractérisation des tumeurs neuroendocrines digestives ou thoraciques

15. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

16. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer

17. The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

18. Thirteen-Month registration of patients with gastroenteropancreatic endocrine tumors in France

19. [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]

20. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab

21. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

23. [Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]

24. [What are the real indications for hepatectomies in metastases of colorectal origin?]

25. What to do when faced with digestive cancer in 2005: Recommendations of the French-speaking Federation of Digestive Oncology. Preface,Que faire devant un cancer digestif en 2005? Recommandations de la Fédération Francophone de Cancérologie Digestive (FFCD). Préface

26. Clinical practice guidelines: Standards, options and recommendations - Managing palliative chemotherapy in primary health care of patients with metastatic colorectal cancer (Update 2003),Recommandations pour la pratique clinique: Mise à jour 2003 des standards, options et recommandations pour la prise en charge par chimiothérapie palliative de première ligne des patients atteints d'un cancer colorectal métastatique

27. [Effect of alcohol and cirrhosis on the presence of Helicobacter pylori in the gastric mucosa]

28. [Control of perfusion by angioscintigraphy during hepatic intra-arterial chemotherapy]

34. [Irinotecan in combination for colon cancer]

35. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial]

37. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer

38. A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology

39. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer

40. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

41. Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program

42. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

43. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies

44. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

45. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone

46. Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development

47. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

Catalog

Books, media, physical & digital resources